Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Non-Deal Roadshow (July 2025)
35 slides from Arovella Therapeutics's roadshow presentation, Jul 2, 2025
Slide 1: ASX Release: Investor Presentation
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 2 July 2025 INVESTOR PRESENTATION MELBOURNE, AUSTRALIA 2 JULY 2025: Arovella Therapeutics Ltd (ASX: ALA) is pleased to provide an update to investors in the form of the attached presentation. This presentation will be used at Arovell
Slide 2: Forward-looking statements
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 For more information, visit www.arovella.com This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third part
Slide 3: Non-deal roadshow July 2025
ASX:ALA For personal use only Non-deal roadshow July 2025
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment 4. Whilst this presentation is based on information from sources which are advice. The presentation is not intended to be comprehensive or provide all considered reliable, no representation or warranty, expres
Slide 5: Arovella's strengths
Arovella’s strengths Off-the-Shelf iNKT Addressing Key Strategic Strong Cell Platform Unmet Need Acquisitions Leadership Group For personal use only Developing off-the-shelf iNKT Our iNKT cell platform is Focused on acquiring Leadership team and Board cell therapies to target blood well positioned t
Slide 6: Arovella's strong leadership group
Arovella’s strong leadership group Leadership For personal use only linkedin with circle" Icon - Download for free – Iconduck linkedin with circle" Icon - Download for free – Iconduck linkedin with circle" Icon - Download for free – Iconduck linkedin with circle" Icon - Download for free – Iconduck
Slide 7: Recent cell therapy transactions
Recent cell therapy transactions1 Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) Jun-25 Acqusition In vivo CAR Phase 1 $2,100 $0 Up to $2,100 Mar-25 Acquisition In vivo CAR Phase 1 $425 $575 $1,000 For personal use only No
Slide 8: Financial overview
Financial overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA For personal use only Market capitalisation1 $130.2 million 40,000,000 $0.18 Shares on issue 1,183.9 million 52-week low / high $0.068 / $0.210 30,000,000 Cash Balance (31 Mar, 2025) $23.5 million $0.12 20,000,000 M
Slide 9: Highlights for CY 2025 to date
Highlights for CY 2025 to date… Completed $15 million placement to fully fund enrolment and report For personal use only initial safety and efficacy data for the phase 1 trial for ALA-101 Cash and cash equivalents Successfully transferred the ALA-101 manufacturing process into at 31 March, 2025 of c
Slide 10: Targeting cancer using cell therapies
For personal use only Targeting cancer using cell therapies 8
Slide 11: Cell Therapy has revolutionised blood cancer treatment
Cell Therapy has revolutionised blood cancer treatment CAR-T cells have demonstrated their curative potential in blood cancers For personal use only Cure Product Approval Year 2024 Revenue CAR-T cells have demonstrated ability to cure 2017 US$1570m3 haematological cancers 2017 US$442m4 Strong Sale
Slide 12: Current CAR-T technology challenges and ALA's solution
Current CAR-T technology challenges ALA’s solution: One CAR-T product only treats the patient who supplied the T cells One CAR-iNKT batch from Manufacturing & supply a healthy donor treats For personal use only T cell chain costs are high multiple patients T cell Each T cells can be manufacturing co
Slide 13: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system For personal use only Innate Immunity Adaptive Immunity ASX:ALA 11
Slide 14: iNKT cells represent a next-generation cell therapy
iNKT cells represent a next-generation cell therapy Properties make them ideal for use in cell therapy Strong safety profile For personal use only ▪ Don’t cause graft versus host disease (GvHD) Innate Front line of the human Immunity immune system ▪ Bridge innate & adaptive immune responses ▪ Contai
Slide 15: A differentiated position
A differentiated position T cell and NK cell sectors are competitive For personal use only T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. ASX:ALA Source: Company analysis based on public information 13
Slide 16: ALA-101 (CAR19-iNKT cells)
For personal use only ALA-101 (CAR19-iNKT cells) A next generation off-the-shelf cell therapy for CD19 expressing cancers 14
Slide 17: ALA-101: enhanced tumour killing in vivo
ALA-101: enhanced tumour killing in vivo ALA-101 rapidly eradicates tumour cells in mice ▪ Tumour cells expressing CD19 and PBS T iNKT CAR19-T ALA-101 For personal use only CD1d were intravenously delivered into mice Ventral ▪ Mice were treated with: ▪ PBS (saline) Day 0 ▪ Unmodified T cells (T) Dor
Slide 18: ALA-101: next generation cell therapy
ALA-101: next generation cell therapy ALA-101 significantly increased survival in mice versus treatment with CAR19-T cells ▪ Tumour cells positive for CD19 and CD1d For personal use only were intravenously delivered into mice ▪ Mice were treated with: P <0.01 ▪ PBS (saline) ▪ Unmodified T cells (T)
Slide 19: ALA-101: spontaneous secondary remission
ALA-101: spontaneous secondary remission ALA-101 activity may persist to eradicate tumour cells following relapse For personal use only ▪ Four mice treated with ALA-101 Ventral had the cancer return to the brain ▪ In all four mice, the cancer was eliminated a second time with no Dorsal additional do
Slide 20: Clinic-ready manufacturing process developed
Clinic-ready manufacturing process developed Semi-automated process suitable for large-scale and late-phase clinical development PHASE 1 CLINICAL TRIAL TECHNOLOGY PRE-CLINICAL LENTIVIRUS MANUFACTURING FDA (IND) / PHASE 1 CLINICAL PHASE 2 CLINICAL For personal use only ACQUISITION CONFIRMATION MANUFA
Slide 21: Pathway to US FDA IND
Pathway to US FDA IND Arovella is working to have the highest chance of a successful IND submission For personal use only Early interactions with the FDA to discuss the Pre-IND proposed clinical program Meeting Generation of data for manufacturing and non- Chemistry, Manufacturing Non-clinical Clini
Slide 22: Positioning the ALA-101 IND for success
Positioning the ALA-101 IND for success IND filing is delayed to maximise the chance of acceptance For personal use only Chemistry Manufacturing and Non-Clinical Clinical controls (CMC) ▪ Process development - complete ▪ In vivo efficacy - complete ▪ CRO selection - ongoing ▪ Tech transfer to cGMP s
Slide 23: ALA-101-001: phase 1 first-in-human study
ALA-101-001: phase 1 first-in-human study Dose escalation and dose expansion study in patients with CD19+ blood cancers Patients with relapsed or refractory CD19+ non-Hodgkin’s For personal use only lymphoma (NHL, including DLBCL, FL, MCL, MZL) and Part 1: Dose Escalation CD19+ leukemias (including
Slide 24: iNKT cells to target solid tumours
iNKT cells to target solid tumours For personal use only Arovella is implementing its strategy to target and kill solid tumours – 90% of newly diagnosed cancer cases1 1. https://www.cancer.gov/types/common-cancers 22
Slide 25: Arovella's strategies to combat solid tumours
Arovella’s strategies to combat solid tumours Arovella is using three approaches to expand the iNKT cell platform into solid tumours For personal use only License novel Armour Create unique cancer targets iNKT cells partnerships Identify and license Enhance the Create partnerships new targets that a
Slide 26: Solid tumours pose challenges to cell therapies
Solid tumours pose challenges to cell therapies iNKT cells have features that may make them useful for treating solid tumours For personal use only Solid tumours are more difficult to treat with cell therapies Access to tumour Lack of antigen iNKT cells: specificity and uniformity Home to tissues an
Slide 27: New CARs
New CARs Add additional CARs for novel targets Arovella’s manufacturing process can be leveraged for multiple cancer types MANUFACTURING For personal use only Isolate iNKT cells Expand to grow billions of CAR-iNKT cells Collect Healthy Engineer iNKT cells to Vial and freeze Donor Blood produce CARs
Slide 28: Introducing Claudin 18.2 (CLDN18.2)
Introducing Claudin 18.2 (CLDN18.2) A promising solid tumour target For personal use only Validated target with first monoclonal antibody approved in Japan and the CLDN18.2 overexpression has been US in 2024 identified in several Gastric cancer types of cancers market alone expected to reach $10.7 b
Slide 29: "Armouring" CAR-iNKT cells
ARMOURING “Armouring” CAR-iNKT cells IL-12-TM (cytokine technology) enhances CAR-iNKT cell activity in solid tumours For personal use only iNKT cells IL-12-TM IL-12-TM Expand more 10x more Superior IL-12-TM is a modified and survive circulating anti-tumour version of IL-12 for longer CAR-iNKT cells
Slide 30: Key benefits of IL-12-TM for CAR-iNKT cells
Key benefits of IL-12-TM for CAR-iNKT cells IL-12-TM enhances antitumor activity of CAR-iNKT cells ▪ Tumour cells positive for GD2 and were For personal use only intravenously delivered into mice before treatment with CAR-iNKT cells ▪ Mice were treated with: ▪ PBS (saline) ▪ GD2-CAR PBS (n=4) ▪ GD2-
Slide 31: Arovella's expanding pipeline
Arovella’s expanding pipeline For personal use only ASX:ALA 29
Slide 32: Upcoming milestones for FY2026
Upcoming milestones for FY2026 Jul Dec Jun 2025 2025 2026 For personal use only ▪ Complete cGMP manufacture and IND enabling ▪ Commence phase 1 study and generate initial data from studies and file an IND application with US FDA for patients in early dose cohorts ALA-101 phase 1 (CD19) ▪ Complete pr
Slide 33: Summary
Summary Novel allogeneic Lead product progressing CAR-iNKT cell platform to clinical trials For personal use only iNKT cells serve as an excellent platform ALA-101, a potential treatment for to develop allogeneic, or “off-the-shelf”, CD19-expressing blood cancers, is cell therapies to treat cancer b
Slide 34: Thank You
ASX:ALA For personal use only Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Slide 35: Cell therapy deal references
Cell therapy deal references 1. https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics,-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in- Immunologyhttps://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html 2. https://www.reu
Arovella Therapeutics — Non-Deal Roadshow (July 2025) on 6ix